IMNN
IMUNON Signs CRADA With National Cancer Institute for IMNN-001
The NCI's Cancer Therapy Evaluation Program will sponsor and fund new trials of IMUNON's DNA-based IL-12 immunotherapy in additional solid tumors.
IMNN
Market-moving news on Imunon (NASDAQ: IMNN): filings, earnings, deals and other events, from REDFILED.